


**PRODUCT: XMD17-109**

<b>ALTERNATE NAMES:</b>	XMD17 109; XMD17109; 11-cyclopentyl-2-[2-ethoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5-methylpyrimido[4,5-b][1,4]benzodiazepin-6-one
<b>CATALOG#:</b>	B1685-5, -25
<b>AMOUNT:</b>	5 mg, 25 mg
<b>STRUCTURE:</b>	
<b>MOLECULAR FORMULA:</b>	C <sub>36</sub> H <sub>46</sub> N <sub>8</sub> O <sub>3</sub>
<b>MOLECULAR WEIGHT:</b>	638.8
<b>CAS NUMBER:</b>	1435488-37-1
<b>APPEARANCE:</b>	Solid powder
<b>SOLUBILITY:</b>	DMSO
<b>PURITY:</b>	>98%
<b>STORAGE:</b>	Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.
<b>DESCRIPTION:</b>	XMD17-109 is a novel, specific ERK-5 inhibitor, which inhibits the ERK5-mediated AP1 transcriptional activity at 30 μM, and has an EC <sub>50</sub> of 4.2 μM.
<b>HANDLING:</b>	Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
<b>REFERENCES:</b>	<ol style="list-style-type: none"><li>Elkins, Jonathan M et al. X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor. Journal of Medicinal Chemistry (2013), 56(11), 4413-4421.</li><li>Wilhelmsen K, et al. Extracellular signal-regulated kinase 5 promotes acute cellular and systemic inflammation. Sci Signal. 2015 Aug 25;8(391):ra86.</li></ol>

**RELATED PRODUCTS:**

- PD184352 (Cat. No. 1585-1, 5, 25)
- EZSolution™ PD184352 (Cat. No. 1871-1)
- PD 98059 (Cat. No. 1666-5)
- EZSolution™ PD 98059 (Cat. No. 1783-5)
- SB 203580 (Cat. No. 1712-1, 5)
- EZSolution™ SB-203580 (Cat. No. 1786-1)
- U0126 (Cat. No. 1668-5)
- Sorafenib (Cat. No. 1594-25, 100)
- VX-702 (Cat. No. 1598-1, 5)

**USAGE:** *FOR RESEARCH USE ONLY! Not to be used in humans*